A mass influx of buzzy ads and even Super Bowl commercials for these products by trendy telehealth companies like Hims & Hers and Ro have pitched ... weight-loss agents—starting with Wegovy in June ...

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned ... February after Hims & Hers ran a controversial commercial about its weight-loss platform during ...

Hims & Hers is shutting down the dermatology business it acquired in 2021, BI has learned. It said it's closing the skincare site Apostrophe to centralize its teledermatology offerings.

Hims & Hers Health (NYSE:HIMS) has taken investors on a wild ride in 2025. The stock surged nearly 200% earlier this year, reaching an all-time high by late February – only to plunge by half in ...

An ad for compounded versions of weight-loss drug semaglutide by telehealth company Hims & Hers has attracted ... in its letter to the FDA that the commercial is "dangerous, blatantly misleading ...

Hims & Hers Health, Inc. (HIMS) shares rallied 5.7% in the last trading session to close at $34.75. This move can be attributable to notable volume with a higher number of shares being traded than ...

The knockoff surge was led by Hims & Hers Health, the telehealth firm that began selling the drugs last spring.

Introduction: What Even Is Hims & Hers Health? In the pop culture of the investing community, Hims & Hers Health, Inc. (NYSE:HIMS) (Hims for short) has been described in all manner of ways ...

The telehealth company had acquired Apostrophe in 2021 for $190 million to expand its skincare offerings. However, HIMS is now integrating Apostrophe’s services into its core Hims & Hers ...